An agreed PIP is the regulatory pathway to market authorization for leniolisib as a treatment of activated phosphoinositide 3-kinase delta syndrome in children

Pharming announces that it has renewed its strategic manufacturing partnership with long-term manufacturing partner Sanofi S.A. The extended 5-year contract which includes options for extensions, ensures the continuation of the downstream processing in the production of RUCONEST®, a recombinant C1 inhibitor product approved for the acute treatment of hereditary angioedema.

Pharming Group presents its preliminary (unaudited) financial report for the first nine months ended September 30, 2021.

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/NASDAQ: PHAR) announces the topline results from two randomized, open label, controlled, pilot clinical trials of patients hospitalized with COVID-19 treated with RUCONEST® (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the 7-point WHO ordinal scale on Day 7.

Recovery continued into Q2 2021 as patient enrollment and product demand increases

Pharming’s CEO Sijmen de Vries and CFO Jeroen Wakkerman look back at the first half of 2021 and the recently published full year financial results.

We are deeply saddened to announce the passing of our former Chairman Drs. Jakob (Jaap) Blaak.